EXEL:NGS-Exelixis Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 33.29

Change

0.00 (0.00)%

Market Cap

USD 4.65B

Volume

7.65M

Analyst Target

USD 30.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Exelixis Inc is a biotechnology company that develops small molecule therapies for the treatment of cancer.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+8.00 (+2.01%)

USD 120.60B
REGN Regeneron Pharmaceuticals Inc

+13.28 (+1.89%)

USD 84.94B
ARGX argenx NV ADR

+4.50 (+0.72%)

USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

-3.18 (-1.30%)

USD 31.66B
BGNE BeiGene Ltd

+1.20 (+0.68%)

USD 20.24B
UTHR United Therapeutics Corporatio..

+4.07 (+1.13%)

USD 16.18B
MRNA Moderna Inc

+0.20 (+0.51%)

USD 16.10B
RPRX Royalty Pharma Plc

+0.33 (+1.32%)

USD 15.27B
SMMT Summit Therapeutics PLC

+0.80 (+4.48%)

USD 13.67B
INCY Incyte Corporation

+1.00 (+1.45%)

USD 13.52B

ETFs Containing EXEL

IDNA iShares Genomics Immunolo.. 6.69 % 0.00 %

+0.15 (+0.25%)

USD 0.12B
XDNA:CA iShares Genomics Immunolo.. 6.61 % 0.00 %

+0.48 (+0.25%)

CAD 5.33M
FBT:LSE First Trust Global Funds .. 4.46 % 0.00 %

-2.50 (0.25%)

USD 8.11M
FBTU:LSE First Trust Global Funds .. 4.46 % 0.00 %

-0.15 (0.25%)

USD 8.11M
HLTH:AU VanEck Global Healthcare .. 2.90 % 0.00 %

+0.03 (+0.25%)

USD 0.06B
FHH:CA First Trust AlphaDEX US H.. 2.37 % 0.77 %

+0.37 (+0.25%)

CAD 0.01B
FXH First Trust Health Care A.. 2.34 % 0.63 %

+0.16 (+0.25%)

USD 1.09B
RAYD Rayliant Quantitative Dev.. 2.16 % 0.00 %

+0.09 (+0.25%)

USD 0.07B
LSAF LeaderSharesTM AlphaFacto.. 1.31 % 0.75 %

+0.07 (+0.25%)

USD 0.15B
JMEE JPMorgan Market Expansion.. 0.81 % 0.00 %

+0.15 (+0.25%)

USD 1.63B
2B77:XETRA iShares Ageing Population.. 0.78 % 0.00 %

-0.06 (0.25%)

USD 0.50B
SCHA Schwab U.S. Small-Cap ETF 0.25 % 0.05 %

-0.03 (0.25%)

USD 18.38B
BBP Virtus LifeSci Biotech Pr.. 0.00 % 0.79 %

+0.23 (+0.25%)

USD 0.02B
CNCR Loncar Cancer Immunothera.. 0.00 % 0.79 %

+0.23 (+0.25%)

USD 0.01B
JHSC John Hancock Multifactor .. 0.00 % 0.50 %

+0.11 (+0.25%)

USD 0.54B
SIXL 6 Meridian Low Beta Equit.. 0.00 % 0.00 %

-0.05 (0.25%)

USD 0.19B
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.00 %

N/A

CAD 0.01B
2B77:F iShares Ageing Population.. 0.00 % 0.00 %

+0.01 (+0.25%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 38.77% 81% B- 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.77% 81% B- 83% B
Trailing 12 Months  
Capital Gain 39.06% 79% B- 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.06% 79% B- 83% B
Trailing 5 Years  
Capital Gain 77.55% 86% B+ 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 77.55% 86% B+ 81% B-
Average Annual (5 Year Horizon)  
Capital Gain 6.22% 54% F 55% F
Dividend Return 6.22% 54% F 52% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 22.20% 94% A 74% C
Risk Adjusted Return 28.01% 82% B 60% D-
Market Capitalization 4.65B 97% N/A 93% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 22.60 27% 43%
Price/Book Ratio 4.42 29% 28%
Price / Cash Flow Ratio 30.22 3% 11%
Price/Free Cash Flow Ratio 14.23 5% 27%
Management Effectiveness  
Return on Equity 20.20% 97% 90%
Return on Invested Capital 5.10% 84% 66%
Return on Assets 12.81% 98% 97%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.